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Abstract
Curcumin is a polyphenol present in turmeric and is credited with anti-inflammatory, antioxidant, and chemopro-
tective properties. Questions remain surrounding curcumin’s bioavailability and the mechanism by which it may 
exert neuroprotective effects. Following PRISMA 2009 guidelines, a systematic review was conducted to identify 
randomized, placebo-controlled trials investigating the effects of curcumin supplementation on cognitive func-
tion in older adults (>50 years). Five databases were searched (CINAHL, Cochrane Library, PubMed, SCOPUS, Web 
of Science) with five studies identified, each using different forms of curcumin and validated cognitive screening 
measures, meeting inclusion criteria. Curcumin doses ranged from between 90 and 4,000 mg/day, with significant 
improvements found in three of the five studies. Firstly, the most recent study found improvements with 90 mg 
of curcumin twice daily in tests of selective reminding (p = 0.002), visual memory (p = 0.01), and attention (p < 
0.0001) over 18 months in non-demented individuals. The second study found improvement in Montreal Cogni-
tive Assessment tool with 1,500 mg/day curcumin over 52 weeks (p = 0.02). Another study found improvement 
in serial three subtraction task responses after 4 weeks compared with the placebo group (p = 0.044). Of the 
adverse events reported (n = 58), gastrointestinal symptoms were most common (n = 34). Before curcumin can 
be recommended to treat or reduce rates of cognitive decline, well-designed trials with standardization in dose, 
method of assessing cognition, and duration, are required to determine the most bioavailable form of curcumin 
with minimal adverse effects.
Keywords: Curcumin; Cognition; Dementia; Alzheimer’s disease; Dietary supple-
ments; Nutraceuticals.
Abbreviations: Aβ, amyloid-beta; AD, Alzheimer’s disease; FDDNP-PET, 2-(1-(6-
[(2-[F-18]fluoroethyl)(methyl)amino]-2-naphthylethylidene)malononitrile positron 
emission tomography; MCI, mild cognitive impairment; MMSE, Mini-Mental State 
Examination; MoCA, Montreal Cognitive Assessment; RCT, randomized controlled 
trial.
Received: December 18, 2018; Revised: March 05, 2019; Accepted: March 06, 2019
*Correspondence to: Nenad Naumovski, Collaborative Research in Bioactives and 
Biomarkers (CRIBB) Group, P.O. Box 5018, University of Canberra, Bruce, ACT, 
2617, Australia. Tel: +61 2 62068719; Fax: +61 2 62015999; E-mail: nenad.nau-
movski@canberra.edu.au
How to cite this article: Seddon N, D’Cunha NM, Mellor DD, McKune AJ, Geor-
gousopoulou EN, Panagiotakos DB, Kellett J, Naumovski N. Effects of Curcumin 
on Cognitive Function—A Systematic Review of Randomized Controlled Trials. 
Exploratory Research and Hypothesis in Medicine 2019;4(1):1–11. doi: 10.14218/
ERHM.2018.00024.
Introduction
The rapid global growth in our ageing population has resulted in an 
increase in neurodegenerative conditions, such as dementia, which 
results in cognitive decline, loss of functional capacity and reduced 
quality of life.1 However, subtle cognitive changes associated with 
ageing are common even in the absence of dementia or mild cog-
nitive impairment (MCI).2 The maintenance of cognitive function 
is vital for healthy ageing and daily functioning. Cognitive func-
tions including memory, attention, processing speed, visuospatial 
perception, and problem-solving decline with ageing and are im-
pacted by both non-modifiable and modifiable risk factors.3,4 Non-
modifiable risk factors include age, sex, and genetics, influencing 
the likelihood of impaired cognitive function, while modifiable 
risk factors include lifestyle, education, and disease management, 
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such as diabetes mellitus and hypertension.2–4 There is increasing 
recognition that addressing modifiable risk and lifestyle factors 
can preserve cognitive function later into life, potentially delaying 
the onset of dementia.
While the prevalence of dementia, particularly its most com-
mon form of Alzheimer’s disease (AD), may be stabilizing in 
some countries, cases of younger-onset AD are increasing, and the 
global rate of people living with dementia has more than doubled 
from 1990 to 2016.5,6 Declining cognitive function, memory and 
behavior are indicative of progressive AD, and at a physiological 
level, AD is characterized by the formation of amyloid plaques and 
neurofibrillary tangles in brain tissue, which contribute to neuro-
degeneration by blocking cell-signaling activity.7,8 The amyloid-
beta (A) protein is the main component of the plaques, which are 
formed in response to cellular degeneration.9 Hyperphosphoryl-
ated tau proteins are the main component of neurofibrillary tan-
gles, and increased tau synthesis is similarly initiated by cellular 
degeneration.9 The neurodegeneration and presence of abnormal 
physiological structures are intermediary stimulants for neuroin-
flammation.10 The inhibition of  and tau formation, and their sub-
sequent disestablishment of plaques and neurofibrillary tangles is 
a current target for pharmacological interventions, which to date 
have proven to be mostly unsuccessful.11
Established treatments for AD include cholinesterase inhibitors, 
such as galantamine, rivastigmine and donepezil, which are widely 
prescribed to treat symptoms of cognitive decline. However, dif-
ficulty in achieving a correct dosage, the timing of intervention, 
and potential adverse events limit the overall effectiveness of such 
treatments.12 Therefore, non-pharmacological treatments, such as 
dietary supplements and nutraceuticals, have come into focus for 
the potential treatment of neurodegenerative conditions.13 In par-
ticular, plant polyphenols are increasingly being investigated for 
their potential in the prevention or treatment neurodegenerative 
conditions, due to their pleotropic activities in the human body.14
Polyphenolic compounds, such as curcumin, are being acknowl-
edged for their associations with various beneficial health effects. 
In particular, the consumption of foods containing polyphenol-rich 
turmeric (Curcuma longa), such as curry, is associated with re-
duced incidence of cognitive decline. In 2006, a cross-sectional 
study of older people found that participants who ‘occasionally’ 
and ‘often or very often’ consumed curry had higher Mini-Mental 
State Examination (MMSE) scores compared to those who ‘never 
or rarely’ consumed curry.15 Turmeric supplementation has been 
associated with alleviation of incontinence, improved recogni-
tion of family, and reductions in agitation, anxiety and irritability 
in people with dementia.16 Together, these findings have led to a 
greater examination of the primary bioactives present in turmeric.
Curcumin is the primary polyphenolic compound of turmeric, 
a bright yellow-colored spice widely used as a flavor and coloring 
agent in gastronomy.8,17 The term ‘curcuminoid’ is used to describe 
the functional group of biochemical agents found in turmeric, of 
which curcumin is the most abundant, while demethoxycurcumin, 
bisdemethoxycurcumin and cyclic curcumin forms are less com-
mon occurring curcuminoids of turmeric.17 Today, curcumin is 
recognized for its potential to contribute to improved outcomes in 
the treatment of metabolic syndrome,18 diabetes mellitus,19 pain,20 
arthritis,21 and symptoms of depression and anxiety.22
The health benefits of curcumin are reported to be due to its 
anti-inflammatory,23–25 antioxidant and chemoprotective prop-
erties,25–27 suggesting that curcumin may also have a role in the 
prevention of AD. Mechanistically, curcumin has been shown to 
inhibit the formation of amyloid-beta (Aβ) fibrils, de-establish 
preformed fibrils and inhibit tau phosphorylation in in vivo and 
in vitro animal models.28–31 Moreover, transgenic mouse models 
of AD have indicated that supplementation with curcumin low-
ers oxidized proteins and inflammatory cytokines in the brain,32 
prevents memory deficits,33 cognitive decline and suppresses be-
havioral deficits.34,35 However, the evidence supporting curcumin 
supplementation in humans to prevent or delay cognitive decline 
remains unclear.
Numerous curcumin formulations aimed to enhance its bioac-
tivity and absorbability have been developed, which may enhance 
neuroprotective effects due to the ability to cross the blood-brain 
barrier. However, the debate remains as to whether curcumin pro-
motes brain health and cognitive function through its activity in the 
brain, or systemically through its effects on gastrointestinal health 
possibly via interactions with the microbiome.36,37 This systematic 
review aims to assess the current evidence surrounding curcumin 
from human randomized controlled trials (RCTs) and its effects on 
cognitive function.
Methods
The review was preregistered with PROSPERO (Registration: 
CRD42017084518; https://www.crd.york.ac.uk/prospero/dis-
play_record.php?RecordID=84518) in accordance with the Pre-
ferred Reporting Items for Systematic Reviews and Meta-analyses 
(PRISMA) statement for systematic reviews.38 The Population, 
Intervention, Comparator, Outcomes and Setting (PICOS) system-
atic review approach was used to guide the systematic review. The 
criteria within each of these categories were as follows:
• Population: Human populations aged 50 years or over that were 
either healthy older people, people with subjective memory 
complaints, MCI or a diagnosed form of dementia;
• Intervention: RCTs investigating the effects of curcumin sup-
plementation for 4 weeks or longer;
• Comparator: Human comparators were required, using a pla-
cebo or control intervention;
• Outcomes: Human data were analyzed according to validated 
cognitive measures, biochemical measures, and adverse effects 
reported; and
• Setting: Any.
Literature search
Literature searches were conducted across five electronic data-
bases (CINAHL, Cochrane Library, PubMed, SCOPUS and Web 
of Science) for studies published from January 2000 to November 
2017. Searches were re-run again in August 2018, with two ad-
ditional articles undergoing full-text review, and only one article 
meeting the inclusion criteria.39 The literature search intended to 
identify the highest quality evidence from double-blind, placebo-
controlled, human clinical trials investigating the effect of curcum-
in supplementation on cognitive function in older adults. Searches 
were performed using the following search terms “curcumin*”, 
“curcuma”, “Curcumin longa”, “turmeric”, “bisdemethoxycur-
cumin”, “desmethoxycurcumin”, “cyclic curcumin” and “cognit*” 
as well as “elder*”, “geriatric”, “older”, “aged” in conjunction 
with “Alzheimer’s disease”, “Alzheimer*”, “dementia”, “neuro-
cognitive impairment”, “mild cognitive impairment”, “memory 
loss”, using Boolean operators AND and OR; the (*) indicates the 
use of wildcard operators. Further studies of interest were identi-
fied through examination of the reference lists of relevant studies 
and previously published review articles. A summary of the search 
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strategy can be found in Figure 1.
Selection criteria
Peer-reviewed journal articles of studies conducted in humans and 
published in the English language after January 2000 were eligible 
for inclusion. Studies investigating participants with a mean age 
over 50 years were of interest to this review due to the increased 
likelihood of impaired cognitive function. Studies were included 
if curcumin supplementation was completed for a minimum dura-
tion of 4 weeks to assess effects on symptoms of cognitive decline. 
Fig. 1. Search strategy and journal selection process flowchart. 
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The primary outcomes of interest were studies reporting cogni-
tive function outcomes via validated cognitive screening methods 
(e.g., MMSE, Montreal Cognitive Assessment (MoCA), Alzhei-
mer’s Disease Assessment Scale-cognitive subscale (ADAS-cog)) 
or diagnosis of a form of dementia. The secondary outcomes were 
biochemical markers, including A plasma levels, t-tau, p-tau, and 
lipids. Biomarkers were used to evaluate the association between 
curcumin supplementation and changes in cognitive function. Ad-
verse effects were also of interest to examine the safety of the cur-
cumin supplements used.
Two researchers (N.S. and N.M.D.) independently conduct-
ed the searches. Using the eligibility criteria, both authors first 
screened based on titles and abstracts. For any articles where this 
was unclear, the article was included in the full-text review. The 
full text of the remaining papers was independently reviewed by 
both authors, and eligible studies were included in the review. Dis-
agreements were discussed to reach consensus with mediation by 
a third researcher (N.N.), when appropriate.
Data extraction and risk of bias assessment
The included articles were extracted (N.S.) and checked for 
consistency (N.M.D.). Data extraction was completed for study 
design, descriptive statistics, type, dose, and timing of the inter-
vention, and results of the primary and secondary outcomes. The 
Cochrane Risk of Bias Tool was used to assess the potential for 
bias by two researchers (N.S. and N.M.D.),40 as it is established 
as the most appropriate assessment tool due to its specificity for 
bias in RCTs (Table 139,41–43). Disagreements were discussed with 
a third researcher (E.N.G). Country of study and funding source 
were also deemed suitable additions to assess the risk of bias.
Results
A total of 652 studies were identified during the initial elec-
tronic database search. Four additional articles were located by 
manual searching (n = 4). After the removal of articles due to 
duplicates (n = 49), inappropriate population (n = 205), incor-
rect study design (n = 333) and insufficient intervention (n = 
62), seven studies remained for full-text assessment. Five trials 
met the inclusion criteria with the remaining two excluded due 
to investigating turmeric and curry consumption.22,39,41–45 All 
included studies were randomized, placebo-controlled, double-
blind, clinical trials.
Study characteristics
The total number of participants enrolled in the included studies 
was 292, with sample sizes ranging from 34 to 96 participants 
(Table 2). The primary outcome for all five studies was validated 
screening measures of cognitive function, while all also measured 
biochemical outcomes,39,41–44 and four reported adverse events 
(Table 3).39,41,42,44 The mean age range of participants was 53.5 
to 85.5 years of age. The combined average age of participants 
was 69.9 years, with three studies assessing Caucasian individu-
als,41–43 one study assessing ethnic Chinese individuals and one 
study that did not define racial demographics.39,44 Three of the 
studies included participants experiencing cognitive decline. Two 
studies included healthy participants,41,43 two recruited partici-
pants with mild to moderate AD,42,44 and one included individuals 
with MCI.39 Duration of curcumin supplementation ranged from 4 
weeks to 78 weeks.
The included studies used a range of cognitive screening meas-
ures. Two studies used the MoCA to evaluate global cognition,39,41 
two used the MMSE,42,44 and one used the ADAS-cog.42 Addi-
tional measures for executive functioning were used in three stud-
ies,39,41,43 visual processing in three studies,39,41,43 verbal memory 
in two studies,39,41 and delayed recall in two studies.39,43 Due to the 
small number of articles identified, and considerable heterogeneity 
across studies, we did not deem the inclusion of a meta-analysis to 
be appropriate at this time.
Table 1.  Assessment of bias risk in reviewed studies
Bias classification Baum et al.44 Ringman et al.42 Cox et al.43 Rainey-Smith et al.41 Small et al.39
Random sequence 
generation
Low Low Low Low Low
Allocation 
concealment
Low Low Low Low Low
Blinding of 
participants and 
personnel
Unclear Low Unclear Low Low
Blinding of outcome 
assessment
Unclear Low Unclear Low Low
Incomplete 
outcome data
Low Low Low Low Low
Selective reporting Low Low Low Low Low
Other bias High Low Low Low Low
Country Hong Kong USA Australia Australia USA
Funding source University research 
grant/Private grant
Research 
foundation/Research 
grant/government/
Private institution
Private 
institution
Research foundation/
Research grant
Research foundation/
Research grant/
Private institution/
Private company
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Dosage and type of curcumin supplementation
The dosage of supplemental curcumin ranged from 0.09 g to 4 g 
per day, and four studies used a bioenhanced curcumin supplement 
while the study by Baum et al. used pure curcumin at two different 
dosages (1 g/day or 4 g/day) (Table 2).39,41–44 One study used Cur-
cumin C3 Complex® (2 or 4 g/day), a combination of curcumin, 
bisdemethoxycurcumin and demethoxycurcumin standardized for 
minimum 95% curcuminoids.42 The study by Cox et al.43 used 
Longvida® curcumin (400 mg/day), an encapsulated lipophilic 
formulation with 80 mg of curcumin. Rainey-Smith et al.41 used 
BCM-95®CG (Biocurcumax™) (1.5 g/day) containing 88% total 
curcuminoids (curcumin, bisdemethoxycurcumin, demethoxycur-
cumin and 7% volatile oils from Curcuma longa) and the trial by 
Small et al.39 used Theracurmin™ (2 × 90 mg/day), a nanoencap-
sulated submicron crystal solid dispersion of curcumin. The trial 
by Baum et al.44 included 120 mg of Ginkgo leaf extract in both 
the two curcumin and comparator groups as a standard treatment 
for AD. The study by Ringman et al.42 also permitted vitamin E 
supplementation up to 2,000 i.u./day and vitamin C up to 0.5 g 
per day. All studies included a placebo group who were treated 
in an identical manner to the intervention group but were given 
capsules,39,41–43 or packets of powder that contained no active in-
gredients and were identical in appearance to those provided to the 
intervention group.44
Results of cognitive outcomes
All five included studies reported on an outcome of cognitive func-
tion (Table 2), with varying results. A study by Baum et al.44 (n = 
34) found no difference between the intervention groups and con-
trol groups in the MMSE at the 6-month follow up (p = 0.43). The 
trial by Ringman et al.42 (n = 36) showed no difference between 
groups in the ADAS-cog (p = 0.26), NPI (p = 0.35) or ADCS-ADL 
(p = 0.72). However, the intervention groups performed worse than 
the placebo group on the MMSE (placebo = 23.2 vs. 2 g = 21.4 
and 4 g = 22.8; p = 0.08). The three more recent trials used bioen-
hanced versions of curcumin.
In 2015, Cox et al.43 (n = 60) used a liposomal encapsulated 
form of curcumin (Longvida®) and reported improvements on 
measures of sustained attention and working memory compared 
with placebo over a 4-week duration. The curcumin group had a 
17% nonsignificant increase in the number of correct responses in 
the serial three subtraction task compared to baseline, whereas the 
placebo group only improved by 3%. However, when the results 
were adjusted for demographic variables, the effect was signifi-
cant (p = 0.044), suggesting the intervention improved working 
memory, psychomotor speed and attention when controlling for 
education and work status.
In 2016, Rainey-Smith et al.41 (n = 96) reported a time-by-
treatment group interaction in the MoCA with Biocurcumax™ 
supplementation over 52 weeks compared to the placebo group 
(p = 0.02). However, no other differences between groups were 
observed in cognition according to the Rey Auditory Verbal Learn-
ing Test (all, p > 0.05), Wechsler Digit Symbol Scale (p = 0.91), or 
Controlled Oral Word Association Task, for both a noncomputer-
ized (p = 0.09) and computerized composite score (p = 0.46).
The most recent study by Small et al.39 showed improvement 
from baseline to 18 months in the Buschke-Fuld Selective Re-
minding Test of verbal memory for the group by time interaction 
and the total score (both, p = 0.002), with no change in the con-
trol group following 18 months of Theracurmin supplementation. 
Only the intervention group displayed improvements in visual 
memory (Brief Visuospatial Memory Test-Revised) from baseline 
to 18 months (p = 0.01). The Theracurmin group also improved 
in attention (Trail Making Test A) after 18 months compared with 
placebo (p < 0.0001). However, it is important to note that both 
groups exhibited improvements in their verbal memory score at 
6 months, representing a potential learning effect. With the Ther-
acumin group performing better at 18 months, the results suggest 
that curcumin supplementation prevented a decline in cognition 
compared with the control group. Overall, these results suggest 
greater improvements in cognitive function with more recent trials 
using bioenhanced versions of curcumin.
Biochemical outcomes
Four of the five studies provided results on the outcomes of dif-
ferent biochemical markers, with varying results.39,42–44 Baum et 
al.44 reported that serum A did not differ by dosage of curcumin, 
and plasma isoprostanes did not change by dosage from baseline 
to 6 months (p = 0.23). Ringman et al.42 reported that the interven-
tion groups had lower hematocrit than the control group (control 
= 42%, 2 g = 41.8%, 4 g = 42.3%; p = 0.014) and the intervention 
groups also had higher blood glucose levels (control = 85.9 mg/
dL, 2 g = 91.6 mg/dL, 4 g = 90.5 mg/dL; p = 0.043) than the con-
trol group. There were no significant changes for the intervention 
groups for A42 (p = 0.98) and A40 (p = 0.29), CSF A42 (p = 0.96), 
Table 3.  Adverse events reported
Adverse Event Reference Curcumin, n (%) Placebo, n (%)
Gastrointestinal symptoms Baum et al.44 4(11.8) 0
Rainey-Smith et al.41 23(0)* 0
Ringman et al.42 3(8.3) 0
Small et al.39 4(19) 2(10.5)
Edema Baum et al.44 1(2.9) 1(2.9)
Fall or dizziness Baum et al.44 2(5.9) 1(2.9)
Hearing impairment Baum et al.44 0 1(2.9)
Respiratory tract infection Baum et al.44 1(2.9) 2(5.9)
Dysphagia like symptoms Ringman et al.42 2 0
*Participants’ results excluded from the final statistical analysis.
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CSF total tau (p = 0.97), CSF p-tau (p = 0.83), and CSF F2- iso-
prostanes (p = 0.08). The study by Cox et al.43 showed significantly 
lower total cholesterol levels in the intervention group compared 
to the control group (p = 0.032). No other significant differences 
on blood biomarkers were noted regarding IL-1, IL-6 and tumor 
necrosis factor α (TNFα), as participants had serum levels below 
measurable evaluation. The study by Small et al.39 performed 2-(1-
(6-[(2-[F-18]fluoroethyl)(methyl)amino]-2-naphthylethylidene)
malononitrile positron emission tomography (FDDNP-PET) scans 
on participants at baseline and 18 months. Compared with con-
trols, accumulation of Aβ and tau was lower in the Theracumin 
group (p = 0.04). FDDNP-PET binding decreased within the cur-
cumin group in the amygdala (between groups: p = 0.07; within 
curcumin group; p = 0.04) and increased in the placebo group 
in the hypothalamus (between groups: p = 0.02; within placebo 
group: p = 0.05). They also measured levels of free curcumin, 
which increased in the intervention group, confirming compliance 
with supplementation.
Adverse events
Adverse events were reported in four studies, with one study re-
porting that the curcumin was well tolerated overall.43 A total of 40 
(13.7%) adverse events were reported in the intervention groups 
compared with only 7 (2.40%) in the control groups. The most 
common adverse event was gastrointestinal symptoms, reported in 
four studies,39,41,42,44 with a total of 34 individuals given the cur-
cumin intervention reporting experiencing these symptoms. Two 
studies showed specific symptoms, including black stools, diar-
rhea, transient abdominal pain, gastritis, and nausea.39,42 It is im-
portant to note that the 23 intervention participants who reported 
adverse events in Rainey-Smith et al.41 were excluded from the 
final statistical analysis. Baum et al.44 reported additional adverse 
events in both intervention and placebo groups, including falls or 
dizziness (n = 2 and n = 1, respectively), edema (n = 1 and n = 
1, respectively) and respiratory tract infections (n = 1 and n = 2, 
respectively). Additionally, one participant in the control group 
experienced hearing impairment. Two participants in the study by 
Ringman et al.42 experienced difficulty swallowing the capsules. 
Small et al.39 reported six participants with gastrointestinal symp-
toms (abdominal pain, gastritis and nausea), comprising four from 
the intervention group and two from the placebo group. Both the 
studies by Small et al.39 and Baum et al.44 found adverse events 
occurring among the control group participants. We can only spec-
ulate that these reported events in the control groups were due to 
the general effects of ageing in populations that may be more sus-
ceptible to illness. For the trials of Longvida® and Theracurmin™ 
that found no or minimal side effects, it is suggested that the is-
sue of gastrointestinal symptoms can be potentially resolved with 
these forms.39,43
Risk of bias assessment
The reviewed studies indicated low levels of bias among the cri-
teria published in the Cochrane tool.40 No articles presented with 
a high, overall risk of overall bias. However, several criteria were 
deemed as “unclear” for the trials by Baum et al.44 and Cox et 
al.43 As the study by Baum et al.44 was published as a letter to the 
editor, this may explain why sufficient detail was not presented to 
assess the risk of bias clearly. There were apparent commercial 
links between four of the five studies. Small et al.39, Ringman et 
al.42, Rainey-Smith et al.41 and Cox et al.43 all obtained their in-
tervention products from private companies and these had been 
provided free of charge. The trials by Ringman et al.42 and Cox et 
al.43 received direct funding from these organizations, which were 
acknowledged in the cited papers.
Discussion
This is the first systematic review of curcumin supplementation 
and its association with cognitive function. Together, the results 
suggest that various formulations of curcumin supplements may 
improve performance on some cognitive domains in older people 
and that supplementation may improve biochemical markers as-
sociated with AD. Three of the five studies found improvement in 
cognitive function when supplementing with curcumin. Two stud-
ies found improvements in MoCA scores and serial three subtrac-
tion task response, respectively.41,43 However, in the most recent 
article included in this systematic review, improvements were 
observed using a new nanoparticle formulation of curcumin in 
measures of memory and attention, and through less accumulation 
of Aβ and tau proteins in the hypothalamus and amygdala.39 This 
study by Small et al.39 was also the longest trial to date, with a total 
time of 18 months. However, when assessing the studies together, 
it is difficult to generalize the results due to considerable heteroge-
neity across trials and the low number of participants overall. The 
major limitation of this systematic review, and curcumin research 
investigating its effects on cognitive function in general, is the 
small number of clinical trials conducted to date.
Supplementation dosage and duration of intervention greatly 
differed amongst the included studies. The earliest studies, those 
by Baum et al.44 and Ringman et al.,42 used between 1–4 g/day 
curcumin, and the study by Rainey-Smith et al.,41 which resulted 
in considerable adverse gastrointestinal symptoms, used 1.5 g/
day. However, the two studies using bioenhanced versions used 
much smaller doses.39,43 Cox et al.43 used 0.4 g/day of Longvida®, 
which contains only 0.08 g of actual curcumin. Small et al.39 pro-
vided 0.09 g of Theracumin twice per day. The development of 
bioenhanced versions of curcumin resulted in lower dosages in the 
studies by Cox et al.43 and Small et al.,39 which appear to reduce 
the likelihood of gastrointestinal distress due to their increased ab-
sorption.25 The high dosages of low-bioavailable curcumin helps 
to explain the gastrointestinal effects observed by Baum et al.44 
and perhaps, the null results reported. Moreover, this study and the 
study by Ringman et al.42 were the only studies to assess cognitive 
function in individuals with an established progressive decline in 
cognitive function. Plausibly, their gastrointestinal function may 
have been disrupted already as is often observed in people living 
with dementia.46 The findings in animal models have suggested 
that there is gut-brain modulation of cognitive function and this 
represents a novel and under-researched area in humans.25 In these 
two studies, the timing of curcumin supplementation in relation to 
the disease course may have affected the findings, as progressive 
cognitive decline was already underway. Nevertheless, gastroin-
testinal symptoms observed in people living with dementia, con-
suming newer formulations of curcumin, are yet to be examined.
Curcumin, in its pure form, appears to be poorly tolerated in 
large dosages (>1 g per day). Participants who consumed more 
than 1 g per day reported some adverse events manifested as gas-
trointestinal symptoms. Similar adverse events have been reported 
in other clinical trials of curcumin. In a systematic review of RCTs 
of treatment of joint arthritis, Daily et al.21 reported six studies that 
found curcumin leading to gastrointestinal complaints. Interesting-
ly, joint pain occurrence had a 2.5% decrease per gram of curcum-
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in, yet it was accepted that curcumin doses were considered safe 
if they did not exceed 1.2 g per day for a period of 4 months.21 As 
such, the dosages prescribed in three of the five studies included 
in this review would not be deemed safe. Based on current recom-
mendations, only the Longvida® and Theracumin studies provided 
safe dosage,39,43 from among the five included trials. Neverthe-
less, Cheng et al.47 examined the chemoprotective properties of 
curcumin on high risk or premalignant lesions in patients with a 
bioenhanced curcumin with dosages as high as 12 g per day and 
reported no toxicity in dosages up to 8 g per day. Therefore, the tol-
erability of specific doses of the different formulations of curcumin 
needs to be assessed.
It is well established that curcumin has relatively low bioavail-
ability, low intestinal absorption, and rapid liver metabolism, with 
the majority being excreted through the faces in 3–6 h.48 This has 
led to the development of bioenhanced formulations used in re-
cent trials with Longvida® that found as much as 100 times more 
bioavailability than naturally occurring curcumin.49 Rainey-Smith 
et al.41 supplemented with BCM-95 CG (Biocurcumax), which is 
reported to be 6.93 times more bioavailable than pure curcumin 
purportedly due to the noncurcuminoid compounds.50 Ringman et 
al.42 and Cox et al.43 also utilized manufactured curcumin sup-
plements Curcumin C3 Complex, and Longvida® Optimized 
Curcumin, respectively. The study by Small et al.39 measured the 
kinetics of curcumin absorption over 6 h and found Theracurmin 
to lead to higher peak concentrations compared with Meriva cur-
cumin and a standardized turmeric extract.
Considerable heterogeneity was seen across trials included in 
this systematic review, with different curcumin formulations, dos-
ages and cognitive outcomes used. For these reasons, a meta-anal-
ysis is not currently considered suitable for this data. Improved 
standardization of study measures in trials may render this feasible 
in the future. The length of studies also varied with the study by 
Cox et al.43 running for 4 weeks, making it difficult to extrapo-
late the results to the same extent as the longer trials. However, 
this group is currently testing Longvida® in a 12 week trial with 
improvements in working memory reported recently in an RCT 
of older Australians (unpublished results).51 While four studies 
measured biochemical outcomes, there was no consistency in the 
markers of interest that were measured. Two studies conducted 
APOE genotyping.39,41 The APOE gene has been identified as the 
most recognized genetic risk for AD and could impact the results 
through unknown mechanisms.52 Also, none of the three most 
recent trials investigated older people that had existing cognitive 
impairments. This review evaluated both healthy individuals and 
those with cognitive impairment. Future studies investigating cur-
cumin in both populations of older people are needed to assess 
curcumin from both a preventative and treatment perspective.
There has been a substantial increase in the number of clinical 
trials investigating curcumin to treat or prevent a range of condi-
tions in recent years. The studies included in the present systematic 
review were conducted within the last 10 years, indicative of the 
modern ideology of natural medicine and a response to the lack 
of new pharmacological treatments for cognitive decline and de-
mentia prevention. This contemporary trend in natural medicine 
will no doubt result in further human clinical trials, potentially 
driven by commercial interest and industry funding. Furthermore, 
curcumin interventions may be more efficacious if the supplemen-
tation is given earlier in life as a preventative measure, rather than 
a curative (or palliative) measure. In 2018, results from RCTs of 
curcumin improved symptoms associated with rheumatoid arthri-
tis and liver dysfunction.53,54 Curcumin has also shown promise in 
improving the metabolic profile of diabetes mellitus, a risk factor 
for the development of AD.19 In recent clinical trials of people with 
diabetes mellitus, curcumin has led to improvements in the lipid 
profile, fasting blood glucose, antioxidant status, and inflammatory 
markers, suggesting that curcumin may be useful as a strategy to 
reduce the risk of AD related risk factors earlier in life.19
Considerable attention has been given to curcumin’s bioavail-
ability and testing of new formulations, including several commer-
cially available, proprietary formulations not used in the reviewed 
studies, such as Meriva® (a phytosomal formulation with curcumi-
noids and lecithin) and CW8 (y-cyclodextrin).49 A recent review 
of curcumin formulation bioavailability compared 11 different 
formulations, identified as NovaSol® (Micellized with Tween-80), 
CurcuWin® (Water-soluble formulation) and Longvida® possess-
ing the highest bioavailability relative to pure curcumin. How-
ever, while the cell signaling mechanisms have been extensively 
investigated, dietary polyphenols are starting to come into focus 
for their benefits, irrespective of low bioavailability. Findings from 
animal studies have shown that curcumin may impact gut health 
through the microbiome by the promotion of bacterial diversity, 
reduced gut permeability and improved tight junction function; all 
of these contribute to a reduction in inflammation.36 More research 
is needed to understand how curcumin exerts protection through 
modulation of the gut-brain axis.
Curcumin is only one of four curcuminoids present in turmer-
ic, being the most abundant and most well studied. The potential 
capacity of curcumin as an antioxidant, anti-inflammatory and 
health promotive agent are far greater than its less known curcumi-
noids.55–57 However, lesser-known curcuminoids, such as bis-
demethoxycurcumin and desmethoxycurcumin, may also provide 
health benefits. Furthermore, research will assess the potential for 
benefits to humans of specific curcumin analogues, such as J147 
(which has been shown to reverse cognitive impairment in mice by 
targeting mitochondrial ATP synthase) and EF24 (which is being 
explored as a novel senolytic agent).58–60
The effects of curcumin on improving cognitive function in 
combination with other nutraceuticals also represent an important 
future area for investigation.25 Recently, curcumin was tested in 
combination with Huperzine A in an open-label study of individu-
als with dementia and MCI.61 A small study (n = 15) found im-
provements in the ADAS-cog (Japanese version) after 12 and 28 
weeks with only 60 mg curcumin with 50 µg active Huperzine 
A, 3 mg piperine and other potentially active ingredients. Trials 
are ongoing, investigating the impact of curcumin in combination 
with omega-3 fatty acids to promote cerebral endothelial vasodila-
tor function synergistically.62 Curcumin is also being tested in con-
junction with a lifestyle intervention involving yoga.63 Combin-
ing curcumin with compounds that cross the blood-brain barrier, 
such as beta-hydroxybutyrate, may enhance its effects centrally.64 
Finally, the design of food products or delivery systems that are 
targeted to specific sites of the small intestine (upper portion of 
the jejunum) may improve the efficacy of curcumin interventions. 
Similar to other polyphenolic compounds, absorption rates may 
differ depending on the method of oral delivery.65
Future research prospect
Curcumin’s pleiotropic effects are becoming more widely under-
stood; however, the mechanisms by which it exerts its benefits to 
cognitive function remain unclear. Curcumin and other polyphe-
nols have low bioavailability but are known to be recycled and 
reabsorbed, delivering improvements in gut health, and a reduction 
in systemic inflammation with chronic consumption. To properly 
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evaluate the effects of curcumin on cognitive function, future acute 
and long-term trials should be conducted assessing the efficacy of 
different formulations of curcumin in crossover trials, analyzing 
by APOE genotype,13 and controlling for potential gut dysbiosis 
pre-randomization. A range of other biochemical measures will 
provide insight into curcumin’s benefits, such as microbiome test-
ing, homocysteine, C-reactive protein and other proinflammatory 
cytokines, and markers of mitochondrial function.
Conclusions
In this first systematic review to evaluate the effects of curcumin 
and cognitive function, the results suggest that novel formulations 
of curcumin are promising strategies to promote cognitive func-
tion. However, despite trials of up to 18 months, there is insuffi-
cient evidence to support curcumin supplementation as an effective 
means of both preventing and treating dementia and symptoms of 
cognitive decline. The current evidence in humans is promising 
but generalizability of the results is limited by the small number of 
trials, relatively small sample sizes, and the considerable variation 
across studies. Future research may focus on examining the role 
of bioavailability to further elucidate the mechanisms by which 
curcumin exerts its pleiotropic effects, through examination of the 
gut-brain axis and relevant biomarkers.
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